Idiopathic Pulmonary Fibrosis - 25 Studies Found

Completed : Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis
: Idiopathic Pulmonary Fibrosis
: 2010-09-30
:
  • Drug: inhaled carbon monoxide

Recruiting : Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis
: Idiopathic Pulmonary Fibrosis
: 2015-12-13
Completed : Safety and Tolerability Study of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis
: Idiopathic Pulmonary Fibrosis
: 2003-12-18
: Drug: FG-3019
Completed : Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis
: Idiopathic Pulmonary Fibrosis
: 2003-10-23
:
  • Drug: bosentan

Recruiting : Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis
: Idiopathic Pulmonary Fibrosis
: 2016-04-01
:
  • Drug: ART-123 380 U/kg/day by

RECRUITING : The Effect of N115 on Coughing in IPF Patients
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with 0.02% benzalkonium chloride preservative, pH 7.
RECRUITING : A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: Specified dose on specified days
RECRUITING : Atezolizumab for Idiopathic Pulmonary Fibrosis
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks
RECRUITING : Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis
: Idiopathic Pulmonary Fibrosis
: 2024-11-21
: 100 mg daily by mouth for 3 weeks This drug inhibits a protein (Bcl-2) that protects cells from undergoing programmed cell death.
RECRUITING : Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
: Idiopathic Pulmonary Fibrosis (IPF)
: 2024-11-21
: Pharmaceutical formulation: CapsulesMode of Administration: Oral
Next >>>